title: Feasibility and benefit of hydroxycarbamide as a long-term treatment for sickle cell disease patients: results from the North West London Sickle Cell Disease Registry.
authors.affiliation: Department of Haematology, Central Middlesex Hospital, London, United Kingdom. annette.gilmore@nhs.net
authors.forename: Annette
authors.initials: A
authors.lastname: Gilmore
authors.forename: Gavin
authors.initials: G
authors.lastname: Cho
authors.forename: Jo
authors.initials: J
authors.lastname: Howard
authors.forename: Mark
authors.initials: M
authors.lastname: Layton
authors.forename: Michele
authors.initials: M
authors.lastname: Afif
authors.forename: Robert George
authors.initials: RG
authors.lastname: Hughes
authors.forename: Nicola J
authors.initials: NJ
authors.lastname: Philpott
authors.forename: Sameer
authors.initials: S
authors.lastname: Patankar
authors.forename: Sally C
authors.initials: SC
authors.lastname: Davies
mesh_terms: D056586:Acute Chest Syndrome / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D054796:Drug Dosage Calculations; D004909:Erythrocyte Indices; D005260:Female; D005319:Fetal Hemoglobin / Q000032:analysis; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008131:London; D008137:Longitudinal Studies; D008297:Male; D012042:Registries; D015996:Survival Rate
chemical_list: D005319:Fetal Hemoglobin; D006918:Hydroxyurea